文献速递产科母胎医学

倍他米松治疗至分娩间隔、重复疗程与胎龄<28周婴儿严重脑室内出血

Betamethasone treatment-to-delivery interval, retreatment, and severe intraventricular hemorrhage in infants <28 weeks' gestation.
PubMed 文献 · Am J Obstet Gynecol · 2024-07-04

本研究为观察性研究,探讨胎龄<28周婴儿中倍他米松治疗至分娩间隔超过9天时严重脑室内出血风险是否增加,以及重复疗程能否降低该风险。结果显示,单疗程后≥10天分娩者严重脑室内出血或死亡风险升高(OR 2.8),重复疗程者风险显著降低(OR 0.10);实践改变后重复疗程率从25%升至87%,严重脑室内出血率从22%降至0%。

要点

  • 单疗程倍他米松后≥10天分娩的<28周婴儿,严重脑室内出血或死亡风险升高(OR 2.8)。
  • 首次剂量后≥10天分娩者中,重复疗程者严重脑室内出血风险显著低于未重复者(OR 0.10)。
  • 鼓励对<28周高分娩风险孕妇早期重复倍他米松后,严重脑室内出血率从22%降至0%。

核心结论

  • 倍他米松对严重脑室内出血的益处似乎在首次剂量后随时间减弱,但第二疗程重复治疗似乎可恢复其有益效应。
  • 鼓励对<28周高分娩风险孕妇更早重复倍他米松,与<28周婴儿严重脑室内出血率降低相关。

研究设计与样本

  • 观察性研究,比较实践改变前(epoch 1)和改变后(epoch 2)的脑室内出血发生率,该实践改变鼓励产科医生对首次倍他米松剂量后>9天仍处<28周高分娩风险孕妇进行重复治疗。
  • 采用广义估计方程技术的逻辑回归进行多变量分析,纳入410例<28周婴儿,其中首次2剂倍他米松疗程后1-9天分娩290例,≥10天(符合重复治疗条件)分娩120例。

主要发现

  • 调整潜在混杂变量后,单疗程倍他米松后≥10天分娩婴儿与1-9天分娩婴儿相比,严重脑室内出血单独或严重脑室内出血或4天前死亡复合结局风险增加(OR 2.8;95%CI 1.2-6.6)。
  • 首次剂量后≥10天分娩的120例婴儿中,64例(53%)接受了第二或重复疗程倍他米松。
  • 接受第二或重复疗程倍他米松的婴儿严重脑室内出血率与1-9天分娩婴儿相似,且显著低于≥10天未重复治疗者(OR 0.10;95%CI 0.02-0.65)。
  • 实践改变后,首次倍他米松疗程后≥10天(且<28周)分娩婴儿的重复治疗率从epoch 1的25%升至epoch 2的87%(P<.001),严重脑室内出血率从22%降至0%(P<.001)。
  • 首次倍他米松剂量后1-9天分娩(不符合重复治疗条件)的婴儿严重脑室内出血率在epoch 1和epoch 2间无变化(分别为12%和11%)。

临床怎么用

  • 作者认为,鼓励对<28周高分娩风险孕妇更早重复倍他米松,与<28周婴儿严重脑室内出血率降低相关。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Antenatal corticosteroids decrease the incidence of severe intraventricular hemorrhage (grades 3, 4) in preterm infants. It is unclear whether their beneficial effects on intraventricular hemorrhage wane with time (as occurs in neonatal respiratory distress) and if repeat courses can restore this effect. Previous randomized controlled trials of betamethasone retreatment found no benefit on severe intraventricular hemorrhage rates. However, the trials may have included an insufficient number of infants at risk for intraventricular hemorrhage to be able to adequately address this question. Severe intraventricular hemorrhages occur almost exclusively in infants born at <28 weeks' gestation, whereas only 7% (0%-16%) of the retreatment trials' populations were <28 weeks' gestation. OBJECTIVE: This study aimed to determine if the risk for severe intraventricular hemorrhage in infants delivered at <28 weeks' gestation increases when the betamethasone treatment-to-delivery interval increases beyond 9 days and to determine if betamethasone retreatment before delivery decreases the rate of hemorrhage. STUDY DESIGN: This was an observational study that examined the incidence of intraventricular hemorrhage before (epoch 1) and after (epoch 2) a practice change that encouraged obstetricians to retreat pregnant women still at high risk for delivery before 28 weeks' gestation when >9 days elapsed from the first dose of betamethasone. Multivariable analyses with logistic regression using generalized estimating equation techniques were conducted to examine the rates of intraventricular hemorrhage among 410 infants <28 weeks' gestation who were either delivered between 1 to 9 days (n=290) after the first 2-dose betamethasone course or ≥10 days (and eligible for retreatment) after the first course (n=120). RESULTS: After adjusting for potential confounding variables, infants who were delivered ≥10 days after a single betamethasone course had an increased risk for either severe intraventricular hemorrhage alone or the combined outcome severe intraventricular hemorrhage or death before 4 days (odds ratio, 2.8; 95% confidence interval, 1.2-6.6) when compared with infants who were delivered between 1 and 9 days after betamethasone. Among the 120 infants who were delivered ≥10 days after the first dose of betamethasone, 64 (53%) received a second or retreatment course of antenatal betamethasone. The severe intraventricular hemorrhage rate in infants whose mothers received a second or retreatment course of betamethasone was similar to the rate among infants who delivered within 1 to 9 days and significantly lower than among those who delivered ≥10 days without retreatment (odds ratio, 0.10; 95% confidence interval, 0.02-0.65). Following the change in guidelines, the rate of retreatment in infants who were delivered ≥10 days after the first betamethasone course (and before 28 weeks) increased from epoch 1 to epoch 2 (25% to 87%; P<.001) and the rate of severe intraventricular hemorrhage decreased from 22% to 0% (P<.001). In contrast, the rate of severe intraventricular hemorrhage among infants who were delivered 1 to 9 days after the initial betamethasone dose (who were not eligible for retreatment) did not change between epochs 1 and 2 (12% and 11%, respectively). CONCLUSION: Although betamethasone's benefits on severe intraventricular hemorrhage appear to wane after the first dose, retreatment with a second course seems to restore its beneficial effects. Encouraging earlier retreatment of women at high risk for delivery before 28 weeks was associated with a lower rate of severe intraventricular hemorrhages among infants delivered at <28 weeks' gestation.

来源:Am J Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Clyman RI, Rosenstein MG, Liebowitz MC, et al. Betamethasone treatment-to-delivery interval, retreatment, and severe intraventricular hemorrhage in infants <28 weeks' gestation. Am J Obstet Gynecol. 2024. PMID: 38971464. doi:10.1016/j.ajog.2024.06.048

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。